Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dienogest + micronized progesterone is a combination drug consisting of two different synthetic and natural progestogens. **Dienogest** is a synthetic progestin with high specificity for the progesterone receptor, antiandrogenic properties, and is used primarily for endometriosis and as a component of contraceptives. Its mechanism includes ovulation inhibition, endometrial atrophy, and suppression of estradiol production, leading to the regression of endometriotic tissue. **Micronized progesterone** is a natural form of progesterone processed to improve oral bioavailability, used for hormone replacement therapy, endometrial protection, and treatment of menstrual disorders. This combination, though not a standard or well-established marketed formulation per current available literature, would conceptually provide both potent endometrial effects (from dienogest) and systemic progestogenic support (from micronized progesterone), possibly for the treatment of endometriosis or hormone therapy settings. No specific brand or product is identified or widely marketed as this exact combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dienogest + micronized progesterone.